Encrpc

Encrpc Uses, Dosage, Side Effects, Food Interaction and all others data.

Encrpc is an androgen receptor inhibitor for the treatment of castration-resistant prostate cancer. FDA approved on August 31, 2012.

Resitance to enzalutamide therapy has been observed. This may occurred due to an upregulation of NF-κB2/p52.

Trade Name Encrpc
Availability Prescription only
Generic Enzalutamide
Enzalutamide Other Names Enzalutamida, Enzalutamide
Related Drugs estradiol, Premarin, Xtandi, Casodex, Zytiga, Lynparza
Weight 40mg
Type Capsule
Formula C21H16F4N4O2S
Weight Average: 464.436
Monoisotopic: 464.093009286
Protein binding

Enzalutamide is 97% to 98% bound to plasma proteins, primarily albumin. N-desmethyl enzalutamide is 95% bound to plasma proteins.

Groups Approved
Therapeutic Class
Manufacturer Intas Pharmaceuticals Ltd
Available Country India
Last Updated: September 19, 2023 at 7:00 am
Encrpc
Encrpc

Uses

Encrpc is an androgen receptor inhibitor used to treat castration-resistant prostate cancer.

Encrpc is indicated for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel.

Encrpc is also used to associated treatment for these conditions: Metastatic Castration Resistant Prostate Cancer

How Encrpc works

Encrpc is a competitive androgen receptor inhibitor that effects multiple stages of the signalling pathway. It is able to inhibit androgen binding to its receptor, androgen receptor nuclear translocation, and subsequent interaction with DNA. As a result, proliferation of prostate cancer cells decreases which ultimately leads to apoptosis and decreased tumour volume.

Toxicity

The most common adverse reactions (≥ 5%) are asthenia/fatigue, back pain, diarrhea, arthralgia, hot flush, peripheral edema, musculoskeletal pain, headache, upper respiratory infection, muscular weakness, dizziness, insomnia, lower respiratory infection, spinal cord compression and cauda equina syndrome, hematuria, paresthesia, anxiety, and hypertension.

Food Interaction

  • Avoid St. John's Wort. This herb induces the CYP3A4 metabolism of enzalutamide and may reduce its serum concentration.
  • Take with or without food.

Encrpc Disease Interaction

Moderate: renal impairment, seizures

Volume of Distribution

Apparent volume of distribution (Vd/F), single oral dose = 110 L

Elimination Route

The pharmacokinetic profile of enzalutamide and N-desmethyl enzalutamide (its major active metabolite) is described by a linear two-compartment model with first-order absorption. Encrpc also accumulates. Food does not affect its absorption. Tmax, prostate cancer patients = 1 hour (range of 0.5-3 hours); Cmax, steady state, enzalutamide = 16.6 μg/mL; Cmax, steady state, N-desmethyl enzalutamide = 12.7 μg/mL; Time to steady state, daily dosing = 28 days;

Half Life

The mean terminal half-life (t1/2) for enzalutamide in patients after a single oral dose is 5.8 days (range 2.8 to 10.2 days). Following a single 160 mg oral dose of enzalutamide in healthy volunteers, the mean terminal t1/2 for N-desmethyl enzalutamide is approximately 7.8 to 8.6 days.

Clearance

Apparent clearance (CL/F), single oral dose = 0.56 L/h (range of 0.33 - 1.02 L/h)

Elimination Route

Encrpc is primarily eliminated by hepatic metabolism. 71% of the dose is recovered in urine (including only trace amounts of enzalutamide and N-desmethyl enzalutamide), and 14% is recovered in feces (0.4% of dose as unchanged enzalutamide and 1% as N-desmethyl enzalutamide).

Innovators Monograph

You find simplified version here Encrpc

*** Taking medicines without doctor's advice can cause long-term problems.
Share